GERON CORP
GERNNASDAQTrading Snapshot
- Day Range
- $0.84 – $1.05
- 52-Week Range
- $1.04 – $2.01
- Volume (shares)
- 81,673,530
- Avg Volume (shares)
- —
- Shares Outstanding
- 642.5M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- $184M
- Last Q Revenue
- $57M
- P/E Ratio
- —
- P/S Ratio
- 3.7x
- EPS (TTM)
- $-0.10
- Dividend Yield
- —
- Dilution (1yr)
- +3.3%
GERON CORP
GERN
StockOtter · stockotter.spaceAbout GERON CORP
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Penny Stock Geron Ends Advanced Cancer Study, Shifts Focus to Commercial Growth
Geron Corporation (NASDAQ:GERN) shares plunged on Wednesday after the company halted its late-stage cancer program.
Geron discontinues late-stage trial of blood cancer drug
Geron said on Wednesday it would discontinue a late-stage trial testing its treatment for patients with a form of rare blood cancer.
Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis
FOSTER CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage hematology biopharmaceutical company, today announced the decision to discontinue the Phase 3 IMpactMF trial eva
Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026
FOSTER CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announce
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today reported
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket p